vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.
OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $7.6M, roughly 1.7× Marygold Companies, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -488.0%, a 480.4% gap on every dollar of revenue. On growth, Marygold Companies, Inc. posted the faster year-over-year revenue change (-4.5% vs -22.4%). Over the past eight quarters, Marygold Companies, Inc.'s revenue compounded faster (-1.5% CAGR vs -5.3%).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
MGLD vs OCUL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $13.3M |
| Net Profit | $-576.0K | $-64.7M |
| Gross Margin | 74.0% | 88.0% |
| Operating Margin | -8.3% | -526.5% |
| Net Margin | -7.5% | -488.0% |
| Revenue YoY | -4.5% | -22.4% |
| Net Profit YoY | 67.0% | -33.6% |
| EPS (diluted) | $-0.01 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $13.3M | ||
| Q3 25 | $7.0M | $14.5M | ||
| Q2 25 | $7.2M | $13.5M | ||
| Q1 25 | $7.0M | $10.7M | ||
| Q4 24 | $8.0M | $17.1M | ||
| Q3 24 | $7.9M | $15.4M | ||
| Q2 24 | $8.3M | $16.4M | ||
| Q1 24 | $7.9M | $14.8M |
| Q4 25 | $-576.0K | $-64.7M | ||
| Q3 25 | $-356.0K | $-69.4M | ||
| Q2 25 | $-1.5M | $-67.8M | ||
| Q1 25 | $-1.0M | $-64.1M | ||
| Q4 24 | $-1.7M | $-48.4M | ||
| Q3 24 | $-1.6M | $-36.5M | ||
| Q2 24 | $-1.9M | $-43.8M | ||
| Q1 24 | $-529.0K | $-64.8M |
| Q4 25 | 74.0% | 88.0% | ||
| Q3 25 | 77.0% | 87.8% | ||
| Q2 25 | 67.8% | 85.6% | ||
| Q1 25 | 75.0% | 88.2% | ||
| Q4 24 | 74.1% | 92.8% | ||
| Q3 24 | 73.1% | 89.9% | ||
| Q2 24 | 72.5% | 90.8% | ||
| Q1 24 | 70.5% | 91.0% |
| Q4 25 | -8.3% | -526.5% | ||
| Q3 25 | -18.2% | -472.3% | ||
| Q2 25 | -16.5% | -502.6% | ||
| Q1 25 | -21.4% | -597.5% | ||
| Q4 24 | -22.8% | -296.1% | ||
| Q3 24 | -27.4% | -298.2% | ||
| Q2 24 | -33.3% | -265.1% | ||
| Q1 24 | -18.7% | -214.0% |
| Q4 25 | -7.5% | -488.0% | ||
| Q3 25 | -5.1% | -477.3% | ||
| Q2 25 | -20.4% | -503.9% | ||
| Q1 25 | -14.4% | -598.7% | ||
| Q4 24 | -21.8% | -283.3% | ||
| Q3 24 | -20.1% | -236.6% | ||
| Q2 24 | -22.5% | -266.3% | ||
| Q1 24 | -6.7% | -438.9% |
| Q4 25 | $-0.01 | $-0.27 | ||
| Q3 25 | $-0.01 | $-0.38 | ||
| Q2 25 | $-0.04 | $-0.39 | ||
| Q1 25 | $-0.02 | $-0.38 | ||
| Q4 24 | $-0.04 | $-0.25 | ||
| Q3 24 | $-0.04 | $-0.22 | ||
| Q2 24 | $-0.05 | $-0.26 | ||
| Q1 24 | $-0.01 | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $737.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.7M | $654.3M |
| Total Assets | $27.8M | $808.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $737.1M | ||
| Q3 25 | $12.5M | $344.8M | ||
| Q2 25 | $12.8M | $391.1M | ||
| Q1 25 | $15.6M | $349.7M | ||
| Q4 24 | $14.9M | $392.1M | ||
| Q3 24 | $17.5M | $427.2M | ||
| Q2 24 | $15.0M | $459.7M | ||
| Q1 24 | $16.1M | $482.9M |
| Q4 25 | $22.7M | $654.3M | ||
| Q3 25 | $22.9M | $258.2M | ||
| Q2 25 | $23.0M | $305.9M | ||
| Q1 25 | $24.3M | $265.9M | ||
| Q4 24 | $23.4M | $315.3M | ||
| Q3 24 | $25.5M | $352.0M | ||
| Q2 24 | $26.6M | $377.7M | ||
| Q1 24 | $28.4M | $408.0M |
| Q4 25 | $27.8M | $808.1M | ||
| Q3 25 | $28.4M | $410.9M | ||
| Q2 25 | $30.4M | $451.3M | ||
| Q1 25 | $33.5M | $405.9M | ||
| Q4 24 | $33.0M | $457.9M | ||
| Q3 24 | $35.9M | $490.4M | ||
| Q2 24 | $32.9M | $517.1M | ||
| Q1 24 | $33.7M | $538.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $-54.2M |
| Free Cash FlowOCF − Capex | — | $-57.1M |
| FCF MarginFCF / Revenue | — | -430.9% |
| Capex IntensityCapex / Revenue | 0.0% | 21.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-216.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $-54.2M | ||
| Q3 25 | $-533.0K | $-50.7M | ||
| Q2 25 | $-3.3M | $-55.2M | ||
| Q1 25 | $-1.2M | $-44.7M | ||
| Q4 24 | $-770.0K | $-39.4M | ||
| Q3 24 | $-893.0K | $-36.6M | ||
| Q2 24 | $-1.9M | $-24.8M | ||
| Q1 24 | $-658.0K | $-33.9M |
| Q4 25 | — | $-57.1M | ||
| Q3 25 | $-562.0K | $-56.7M | ||
| Q2 25 | $-3.4M | $-56.5M | ||
| Q1 25 | — | $-46.6M | ||
| Q4 24 | $-776.0K | $-39.6M | ||
| Q3 24 | $-940.0K | $-36.6M | ||
| Q2 24 | $-2.0M | $-25.5M | ||
| Q1 24 | — | $-34.1M |
| Q4 25 | — | -430.9% | ||
| Q3 25 | -8.1% | -390.0% | ||
| Q2 25 | -46.8% | -419.7% | ||
| Q1 25 | — | -435.6% | ||
| Q4 24 | -9.7% | -232.0% | ||
| Q3 24 | -11.9% | -237.6% | ||
| Q2 24 | -23.8% | -155.4% | ||
| Q1 24 | — | -231.1% |
| Q4 25 | 0.0% | 21.4% | ||
| Q3 25 | 0.4% | 41.2% | ||
| Q2 25 | 0.7% | 9.3% | ||
| Q1 25 | 0.0% | 18.1% | ||
| Q4 24 | 0.1% | 1.2% | ||
| Q3 24 | 0.6% | 0.6% | ||
| Q2 24 | 0.7% | 4.5% | ||
| Q1 24 | 0.0% | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
OCUL
Segment breakdown not available.
